Advertisement
Organisation › Details
Pacira BioSicences Inc. (Nasdaq: PCRX)
Pacira BioSciences, Inc. (Nasdaq: PCRX) is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. *
Start | 2021-01-26 existent | |
Industry | pain drug | |
Industry 2 | tissue engineering / regenerative medicine | |
City | n. a. Parsippany, NJ | |
Address record changed: 2021-01-26 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (1/26/21). "Press Release: GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases". | ||
Record changed: 2023-07-10 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top